TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

NCT07052370 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancy

Interventions

DRUG: Thymoglobulin
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Thiotepa
DRUG: Melphalan
DRUG: Mesna
DRUG: Filgrastim
DRUG: Blinatumomab
DEVICE: CliniMACS

Sponsor

St. Jude Children's Research Hospital